Send to

Choose Destination
Biotechnol Rep (Amst). 2017 May 17;15:24-26. doi: 10.1016/j.btre.2017.05.002. eCollection 2017 Sep.

Dusquetide: Reduction in oral mucositis associated with enduring ancillary benefits in tumor resolution and decreased mortality in head and neck cancer patients.

Author information

Radiation Oncology, University of Kentucky, 800 Rose Street, Lexington, KY, 40536, USA.
Gibbs Cancer Center, Spartanburg Regional Hospital, 101 E Wood, Spartanburg, SC, 29303, USA.
Veteran's Affairs Long Beach Hospital, 5901 E 7th Street, Mail Code 114A, Long Beach, CA, 98022, USA.
Department of Medicine, University of Michigan Health System,1500 E Medical Center Drive, Ann Arbor, MI, 48109, USA.
Department of Radiation Oncology, Willis-Knighton Cancer Center,2600 Kings Highway, Shreveport, LA, 71103, USA.
Division of Hematology and Oncology, Washington University, 660 South Euclid Avenue, Saint Louis, MO, 63110, USA.
Department of Hematology and Oncology, Wake Forest Health Sciences Medical Center, 1 Medical Center Blvd., Winston-Salem, NC, 27157, USA.
PharPoint Research, 5003 S Miami Blvd #100, Durham, NC, 27703, USA.
Oral Medicine and Diagnostic Services, Dana Farber/Harvard Cancer Center, Boston, MA, USA.
Biomodels LLC,313 Pleasant Street, Watertown, MA 02472, USA.
Soligenix Inc., 29 Emmons Drive, Suite C-10, Princeton, NJ, 08540, USA.


Innate immunity is a key component in the pathogenesis of oral mucositis, a universal toxicity of chemoradiation therapy (CRT). Dusquetide, a novel Innate Defense Regulator, has demonstrated both nonclinical and clinical efficacy in ameliorating severe oral mucositis (SOM). Long term follow-up studies from the Phase 2 clinical study evaluating dusquetide as a treatment for SOM in head and neck cancer (HNC) patients receiving CRT have now been completed. Extended analysis indicates that dusquetide therapy was well-tolerated and did not contribute to increased infection, tumor growth or mortality. Potential ancillary benefits of duquetide therapy were also identified.


CRT, chemoradiation therapy; Cancer supportive care; Dusquetide; HNC, head and neck cancer; Head and neck cancer; IDR, innate defense regulator; Immune; Innate; OM, oral mucositis; Oral mucositis; SOM, severe oral mucositis

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center